<DOC>
	<DOCNO>NCT00459771</DOCNO>
	<brief_summary>Evaluating effect angiotensin II-receptor ( AT1 ) blocker candesartan v placebo prevention trastuzumab-associated cardiotoxicity patient primary breast cancer treat trastuzumab .</brief_summary>
	<brief_title>Evaluating Effect Candesartan v Placebo Prevention Trastuzumab-associated Cardiotoxicity</brief_title>
	<detailed_description>Prospective , randomized pharmacological intervention study Primary objective : - determine whether concurrent ATII-antagonist treatment prevent trastuzumab-related cardiotoxicity , define decline LVEF 15 % decrease absolute value &lt; 45 % Secondary objective : - To determine 'Brain Natriuretic Peptide ' ( NT-proBNP ) troponin T use surrogate marker monitor trastuzumab-associated cardiotoxicity - To determine genetic variability relevant gene HER2 gene ( assess single nucleotide polymorphism [ SNPs ] kinase domain ) explore correlation trastuzumab induced cardiotoxicity 3 ) To determine reversibility decrease leave ventricular ejection fraction ( LVEF ) associate trastuzumab treatment Arm I : placebo Arm II : AT1 blocker candesartan ( 32 mg/day ; run 16 mg week 1 ) Randomization : chemotherapy treatment period . Study period : chemotherapy period , trastuzumab treatment period 26 week follow discontinuation trastuzumab treatment thereafter 1 month follow-up end placebo AT1 blocker . Candesartan treatment start day first infusion trastuzumab continue 26 week end treatment trastuzumab . Women primary HER2 positive breast cancer consider adjuvant systemic treatment anthracycline contain chemotherapy trastuzumab . Before start anthracycline treatment : - Medical history , physical examination - New York Heart Association ( NYHA ) score - Cardiac questionnaire - Electrocardiogram - MUGA scan - Laboratory assessment ; hemoglobin , hematocrit , white blood cell count , platelet count , serum creatinine , sodium , potassium , calcium , thyroid stimulate hormone , glucose , cholesterol , bilirubin , alkaline phosphatase , ASAT/ALAT , LDH , albumin , NT-proBNP , troponin T analysis - Pregnancy test - Genotype analysis Every chemotherapy cycle - Laboratory assessment ; hemoglobin , hematocrit , white blood cell count , platelet count , serum creatinine , sodium , potassium , calcium , glucose , bilirubin , alkaline phosphatase , ASAT/ALAT , LDH , albumin , ( NT-proBNP , troponin T analysis ) Before start trastuzumab treatment : - Physical examination - New York Heart Association ( NYHA ) score - Cardiac questionnaire - Electrocardiogram - MUGA scan - Laboratory assessment ; hemoglobin , hematocrit , white blood cell count , platelet count , serum creatinine , sodium , potassium , calcium , glucose , bilirubin , alkaline phosphatase , ASAT/ALAT , LDH , albumin , NT-proBNP , troponin T analysis After 3 , 6 9 month trastuzumab : - Physical examination - New York Heart Association ( NYHA ) score - Cardiac questionnaire - MUGA scan - Laboratory assessment ; hemoglobin , hematocrit , white blood cell count , platelet count , serum creatinine , sodium , potassium , calcium , glucose , bilirubin , alkaline phosphatase , ASAT/ALAT , LDH , albumin , NT-proBNP , troponin T analysis After 1 year trastuzumab , 26 week last trastuzumab administration : - Physical examination - New York Heart Association ( NYHA ) score - Cardiac questionnaire - Electrocardiogram - MUGA scan - Laboratory assessment ; hemoglobin , hematocrit , white blood cell count , platelet count , serum creatinine , sodium , potassium , calcium , glucose , bilirubin , alkaline phosphatase , ASAT/ALAT , LDH , albumin , NT-proBNP , troponin T analysis The primary endpoint study deterioration cardiac function define decline LVEF 15 % absolute value 45 % year trastuzumab . From previous study estimate 30 % patient treat trastuzumab show deterioration LVEF . A total 200 patient receive trastuzumab candesartan trastuzumab placebo double blind placebo-controlled study . The number patient randomize ( = chemotherapy period ) trial shall 200 small number patient might drop start therapy trastuzumab . This number exactly determine beforehand .</detailed_description>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<criteria>Women age ≥18 year WHO : ≤ 2 Strongly HER2positive breast cancer , define immunohistochemistry score 3+ use HercepTestTM , gene amplification fluorescence situ hybridization , chromogenic situ hybridization ( CISH ) . Serum creatinine &lt; 140 umol/l creatinine clearance &gt; 50 ml/min ( CockcroftGault formula ) Thyroid stimulate hormone 0.53.9 MU/l Blood pressure systolic ≥ 140 mmHg diastolic ≥ 90 mmHg acceptable randomization . However prior first administration trastuzumab blood pressure regulate systolic ≥ 100 mmHg ≤ 180 mmHg diastolic ≥ 60 mmHg ≤ 100 mmHg . ( blood pressure regulate accord guideline appendix 5 ) LVEF ³ 50 % assess multigated angiography ( MUGA ) cardiac ultrasound Adjuvant regimen : trastuzumab start ≥ 3 week day 1 last anthracycline chemotherapy cycle Trastuzumab treatment accord standard medical care Written inform consent participate study Prior anthracycline chemotherapy regimen antiHER2 therapy , prior biologic immunotherapy breast cancer treatment malignancy Previous malignancy require chemotherapy radiotherapy Uncontrolled serious concurrent illness Patients New York Heart Association ( NYHA ) class II/III/IV congestive heart failure Myocardial infarction &lt; 6 month randomization Treatment ACE inhibitor , ATII blocker , lithium . Patients treat ACE inhibitor , ATII blocker switch ( randomization chemotherapy period ) alternative antihypertensive therapy ; see appendix 5 . History hypersensitivity study medication Pregnancy breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>angiotensin II-receptor ( AT1 ) blocker</keyword>
	<keyword>prevention</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>cardiotoxicity</keyword>
</DOC>